Location History:
- Riehen, CH (1996 - 2003)
- Basel, CH (1997 - 2012)
Company Filing History:
Years Active: 1996-2012
Title: Werner Lesslauer: Innovator in TNF Receptor Research
Introduction
Werner Lesslauer is a prominent inventor based in Basel, Switzerland. He has made significant contributions to the field of biochemistry, particularly in the development of proteins that bind tumor necrosis factor (TNF). With a total of 8 patents to his name, Lesslauer's work has had a substantial impact on medical research and therapeutic applications.
Latest Patents
Lesslauer's latest patents include groundbreaking inventions related to the human TNF receptor. His first patent focuses on non-soluble proteins and soluble or insoluble fragments that bind TNF in homogeneous form. This invention also covers their physiologically compatible salts, particularly proteins with a molecular weight of about 55 or 75 kD under non-reducing SDS-PAGE conditions. Additionally, it outlines a process for isolating such proteins, developing antibodies against them, and identifying DNA sequences that code for these proteins.
The second patent, titled "Human TNF receptor fusion protein," shares similar themes, emphasizing the importance of soluble and non-soluble fragments that bind TNF. This patent also details the processes for their manufacture using transformed pro- and eukaryotic host cells, showcasing Lesslauer's innovative approach to protein engineering.
Career Highlights
Werner Lesslauer is associated with Hoffmann-La Roche Inc., a leading global healthcare company. His work at this esteemed organization has allowed him to collaborate with other notable scientists in the field.
Collaborations
Some of his coworkers include Hansruedi Lotscher and Manfred Brockhaus. Their collective expertise has contributed to advancing research in TNF receptor technology.
Conclusion
Werner Lesslauer's contributions to the field of biochemistry, particularly in TNF receptor research, highlight his innovative spirit and dedication to scientific advancement. His patents reflect a commitment to developing solutions that can potentially transform therapeutic approaches in medicine.